anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Of 816 patients with herpes zoster in clinical studies who were treated with famciclovir, 248 (30.4%) were greater than or equal to 65 years of age and 103 (13%) were greater than or equal to 75 years of age. No overall differences were observed in the incidence or types of adverse events between younger and older patients. Of 610 patients with recurrent herpes simplex (type 1 or type 2) in clinical studies who were treated with famciclovir, 26 (4.3%) were greater than 65 years of age and 7 (1.1%) were greater than 75 years of age. Clinical studies of famciclovir in patients with recurrent genital herpes did not include sufficient numbers of subjects aged 65 years and over to determine whether they respond differently compared to younger subjects.

No famciclovir dosage adjustment based on age is recommended unless renal function is impaired [see Dosage and Administration ( 2.3), Clinical Pharmacology ( 12.3) ]. In general, appropriate caution should be exercised in the administration and monitoring of famciclovir in elderly patients reflecting the greater frequency of decreased renal function and concomitant use of other drugs.
PURPOSE: Accuracy in the diagnosis of HPV-associated oropharyngeal carcinoma (OPSCC) of a rapid, low-cost lateral flow immunochromatographic assay for detecting E6 oncoprotein of HPV-16 and HPV-18 was previously evaluated in a small pilot study. This cross-sectional study aimed to assess on a large case series the sensitivity and specificity of E6 oncoprotein as a diagnostic marker for HPV-associated carcinogenesis in OPSCC.
METHODS: 137 consecutive patients with histologically confirmed OPSCC were enrolled in two hospitals in Northeast Italy. HPV status was determined by PCR for HPV DNA and p16INK4a immunohistochemistry on primary tumor biopsies. An OPSCC was defined as HPV-associated when double positive for high-risk HPV-DNA and p16INK4a overexpression in primary lesion. Cytological samples from primary tumors and metastatic lymph nodes were obtained and tested for HPV16/18 E6 oncoproteins using the lateral flow immunochromatographic assay, which requires between 90 and 120 min to provide a result. Diagnostic performances were calculated as percentage with confidence intervals (CI).
RESULTS: Of the 137 OPSCC cases, 68 (49.6%) were HPV-associated, testing positive for both high-risk HPV-DNA and p16INK4a, with HPV16 predominating (82.4%). An average waiting time of 22 days was observed to obtain the results of p16INK4a and HPV-DNA after primary lesions biopsy. In patients with HPV16/18-associated OPSCC, the HPV16/18 E6 oncoprotein was detected in 59 out of 60 cytological samples from the primary lesion (sensitivity: 98.3%; 95% CI: 91.1-100%) and in 45 out of 51 cytological samples from lymph node metastases (sensitivity: 88.2%; 95% CI: 76.1-95.6%). The E6 oncoprotein assay showed a specificity of 100% in both primary tumors and lymph node metastases.
CONCLUSION: The low-cost lateral flow immunochromatographic assay for detecting HPV16/18 E6 oncoproteins confirmed high accuracy for identifying HPV-associated OPSCC, particularly in primary tumors, suggesting its potential as a valuable diagnostic tool in clinical practice. Its rapid diagnostic capability could significantly accelerate the process of treatment decision-making, enhancing the timely management of patients.
Session 1: Participants will meet individually with a research assistant to discuss their type 2 risk and discuss benefits of engaging in 150 minutes of moderate-to-vigorous physical activity per week. First 30 minutes of each subsequent session will be ideal care (as described above in the control group). Last 30 minutes of sessions 2-6, self-compassion condition participants will learn to apply self-compassion to their prediabetes experience and physical activity. Session 2: Learn about fear of self-compassion and the benefits of self-compassion. Session 3: Yin and Yang of self-compassion. Session 4: Mindfulness. Session 5: Dealing with difficult emotions, loving Kindness and Self-Compassionate motivation. Session 6: Living deeply, self-appreciation and stages of progress.
The invention relates to the field of traditional Chinese medicine and pharmacy, and specifically relates to an external ointment for treating various skin warts. The ointment solves the problem that in the prior art, the methods for treating skin warts have the disadvantages of high cost, bad curative effect, unstable effect, and large side effect. The ointment is prepared from the following components: semen pharbitidis, talcum, balloonflower root, pinellia ternate, ligustrum lucidum, stemona, calamine powder, lanolin, and vaseline. The ointment is prepared by the following steps: grinding and sieving traditional Chinese herbals, mixing to obtain traditional Chinese herbal powder; mixing vaseline and lanolin, heating to a temperature of 70 DEG C, adding traditional Chinese herbal powder and calamine powder, evenly stirring, cooling, and adding glacial acetic acid to obtain the external ointment. The external ointment has the functions of clearing heat, removing toxin, cooling blood, removing stasis, dispelling dampness, and dissipating binds. The heat toxin is removed, the blood stasis is eliminated, and the dampness evil is dissipated, so the warts fall down from skin, the collaterals becomes unobstructed, the disease is cured, no scare is left, patients will not feel painful, and the ointment has a good curative effect on various warts caused by infection of papilloma virus, such as common wart, plantar wart, plane warts, verruca acuminata, and the like, and has the advantages of low price and user-friendliness.
A method of stimulating pigment production in mammalian skin, as well as protecting mammalian skin against ultraviolet damage, is disclosed. Also disclosed is a method of stimulating pigment production in mammalian cells, a method of stimulating melanogenesis in mammalian melanocytes, and a culture medium for stimulating melanin production. Preparations useful in the present methods are additionally disclosed. The methods comprise administering to the epidermis or to the cells DNA fragments, either single- or double-stranded, or a mixture of both, or deoxynucleotides, dinucleotides, or dinucleotide dimers in an appropriate vehicle, such as a liposomal preparation or propylene glycol. The preparations include DNA fragments, deoxynucleotides, dinucleotides, or dinucleotide dimers and an appropriate delivery vehicle, such as liposomes or a propylene glycol. The DNA  fragments, deoxynucleotides, or dinucleotides used in the methods or in the preparations can be ultraviolet-irradiated. The preparations are sunlight independent tanning or melanogenesis-stimulating agent.
Rifampin lowers Dapsone levels 7 to 10-fold by accelerating plasma clearance; in leprosy this reduction has not required a change in dosage. Folic acid antagonists such as pyrimethamine may increase the likelihood of hematologic reactions. 

  


A modest interaction has been reported for patients receiving 100 mg Dapsone daily in combination with trimethoprim 5 mg/kg q6h. On Day 7, the serum Dapsone levels averaged 2.1 ± 1.0 mcg/mL in comparison to 1.5 ± 0.5 mcg/mL for Dapsone alone. On Day 7, trimethoprim levels averaged 18.4 ± 5.2 mcg/mL in comparison to 12.4 ± 4.5 mcg/mL for patients not receiving Dapsone. Thus, there is a mutual interaction between Dapsone and trimethoprim in which each raises the level of the other about 1.5 times.

  


A crossover study1 designed to assess the potential of a drug interaction between Dapsone, 100 mg/day and trimethoprim, 200 mg every 12 hours, in eight asymptomatic HIV positive volunteers (average CD4 count 524 cells/mm3) demonstrated that there was not a significant drug intreraction between Dapsone and trimethoprim. However, an earlier report2 also by Lee et al, in 78 HIV infected patients with acute Pneumocystis carinii pneumonia, receiving Dapsone, 100 mg/day and higher trimethoprim dose, 20 mg/kg/day, demonstrated that the serum levels of Dapsone were increased by 40% and trimethoprim levels were increased by 48% when the drugs were administered concurrently.
The HC intervention will place emphasis on the coach establishing rapport with the participant and assessing and establishing their initial goals using motivational interviewing, HC program goals, plans for future individual sessions. A written copy of personal health goals will be given to patients at the end of the first session. Coaches will aim to meet with participants for individual HC sessions bi-monthly the first 2-3 months followed by monthly for 8 - 9 months to provide information and support regarding health habits focusing sessions on areas related to patient-identified health goals, needs, and barriers to change. Sessions can occur in person or by phone based on patient preference.
Abdominal pain in patients with diverticular disease (DD) can be challenging in clinical practice. Patients with symptomatic uncomplicated diverticular disease (SUDD) and patients with a previous acute diverticulitis (PD) may share a similar clinical pattern, difficult to differentiate from irritable bowel syndrome (IBS). We used standardized questionnaires for DD (short and long lasting abdominal pain) and IBS (following Rome III Criteria) to assess clinical features of abdominal pain, in terms of presence, severity and length, in SUDD and PD patients. One hundred and forty-eight SUDD and 118 PD patients completed all questionnaires. Short-lasting pain was more frequent in SUDD than PD patients (p = 0.007). Number of long-lasting pain episodes was higher in SUDD (6.6 ± 11.9) compared to PD patients (3.4 ± 6.9) (p < 0.001). PD patients reported long-lasting pain more frequently in the lower left abdomen (p < 0.001), while in SUDD it was more frequently diffuse (p = 0.002) or localized in the lower right quadrant (p = 0.009). Features associated with long-lasting pain (fever, confinement to bed, consultations, antibiotic therapy, hospitalization) were more often reported in PD patients. IBS criteria were reported in 28.2% of patients and were more frequent in SUDD than PD patients (37.2% vs 17.1%, p < 0.001). SUDD and PD patients presented different pattern of abdominal pain (length, number of long lasting episodes, site and associated features), with a third reporting overlap with IBS. Further observational studies are needed to better characterize abdominal symptoms in DD patients, especially in those not fulfilling IBS criteria.Trial registration: The REMAD Registry is registered as an observational study in ClinicalTrial.gov (ID: NCT03325829).
NEW MATERIAL:A naphthalene derivative expressed by the formula (R is CnH2n+1; n is 0-4). EXAMPLE:4,6-Bis(butylamino)2,3-dihydro-8-hydroxynaphthalene-1,5-dione. USE:An excellent hair dye, capable of well dyeing the hair in a very low concentration and under milk condition and stably coloring with almost no influence of dyeing condition and having good preservation stability. PREPARATION:3,5-Diamino(or bisalkylamino)-8-hydroxynaphthoquinone is reduced with an reducing agent, e.g. Na2S2O6, etc., in the presence of an alkali, e.g. KOH, NaOH or Na2CO3, etc., in water, alcohol or a mixture solution of water with alcohol or reduced in the presence of zinc in an aqueous solution of hydrochloric acid to afford the aimed compound expressed by the formula. The amount of the compound expressed by the formula to be blended is >=0.05wt%, preferably >=0.1wt% based on the total weight of the hair dye.
OBJECTIVE: This study aimed to determine the incidence of complications after landmark-based paravertebral blocks for breast surgery.
METHODS: The medical records of patients who received a paravertebral block for breast surgery between 2019 and 2022 were reviewed. Patient age, sex, type of procedure, number of injections, volume of injected anesthetic, and possible complications were noted. A record was identified as a possible serious block-related complication if there was concern or treatment for local anesthetic systemic toxicity, pneumothorax, altered mental status, or intrathecal/epidural spread. Other complications recorded were immediate postblock hypotension and nausea/vomiting requiring treatment and unanticipated postsurgical admission. Patients receiving ultrasound-guided paravertebral blocks were excluded from this study.
RESULTS: Over a 3-year period, 979 patients received paravertebral blocks using the landmark technique for breast surgery, totaling 4983 injections. Overall, 6 patients required assessment for postblock issues (0.61%), including hypotension (2 patients), nausea (3 patients), and hypotension + altered mental status (1 patient). This latter patient was identified as having a serious complication related to the paravertebral block (0.1%). This patient had unintentional intrathecal spread and altered mental status that required mechanical ventilation. The incidence of block-related hypotension and nausea requiring treatment was thus 0.31% and 0.31% respectively. Four patients required unanticipated admission, but none were for block-related reasons. No patients in this study were found to have local anesthetic systemic toxicity or pneumothorax.
CONCLUSION: Our study suggests that landmark-based paravertebral blocks for breast surgery result in a very low complication rate and are a safe technique for postsurgical analgesia.
The invention discloses dispersible tablets for preventing and controlling hemorrhagic fever viruses. The dispersible tablets are named according to functions, are used for preventing and controlling the hemorrhagic fever viruses, and not only can be orally taken but also can be taken after being quickly dispersed in water. The dispersible tablets belong to the technical fields of epidemiology, molecular virology, molecular biology, cellular and molecular immunology and modern traditional Chinese medicine science, and various disciplines are mutually fused. The dispersible tablets are used for preventing and controlling Ebola hemorrhagic fever viruses which belong to segmental RNA (ribonucleic acid) viruses, and the segmental RNA viruses are easily mutated. High-risk easily infected persons are infected with the viruses due to low natural immunity and immunodeficiency. The dispersible tablets are proposed by developers and can be used for improving natural immunity, activating immune cells, inducing interferon and resisting the viruses in a broad-spectrum manner. The dispersible tablets are used for preventing the hemorrhagic fever viruses, protecting medical personnel, easily infected children, old people with vital energy deficiency and persons with low immunity, and treating people infected with the hemorrhagic fever viruses.
1,151,188. Polymerization/hair-treating processes. CLAIROL Inc. 12 Aug., 1966 [27 Sept., 1965], No. 36286/66. Heading C3P. [Also in Division D1] A process for colouring or bleaching, and additionally protecting, hair comprises treating hair with an aqueous solution of a water-soluble vinylic monomer having an acid group or a salt derivative thereof and effecting polymerization of the monomer in situ in the presence of a bridging agent capable of bridging polymer chains formed from the monomer, an oxidizing agent and, optionally, an oxidation or non- oxidation type dye. The polymerization and colouring (or bleaching) can be effected simultaneously or sequentially. The oxidizing agent can serve both as polymerization initiator and either as bleaching agent or developer of the oxidation dye. Suitable vinylic monomers include acrylic acid, methacrylic acid, itaconic acid and sodium, potassium, calcium and monoethanolamine salts thereof. As bridging agent there may be used a water-soluble compound of a Group II or III metal, e.g. CaCl 2 , ZnC1 2 , BaCl 2  and Al 2 (SO 4 ) 3 , a difunctional quaternary ammonium compound, or a compound providing an organic monovalent cation, e.g. cetyl pyridinium chloride, cetyl trimethyl ammonium chloride and stearyl amine hydrochloride. Oxidizing agents specified are H 2 O 2 , ammonium, sodium or potassium persulphate, and combinations of H 2 O 2  with these persulphates To facilitate penetration, a swelling agent may additionally be used, e.g. monoethanolamine, NaOH, KOH, NH 3  or Ca(OH) 2 .
CAYSTON was evaluated over a period of 28 days of treatment in a randomized, double-blind, placebo-controlled, multicenter trial that enrolled patients with CF and P. aeruginosa. This trial was designed to evaluate improvement in respiratory symptoms. Patients 7 years of age and older and with FEV1 of 25% to 75% predicted were enrolled. All patients received CAYSTON or placebo on an outpatient basis administered with the Altera Nebulizer System. All patients were required to take a dose of an inhaled bronchodilator (beta-agonist) prior to taking a dose of CAYSTON or placebo. Patients were receiving standard care for CF, including drugs for obstructive airway diseases.

The trial enrolled 164 patients with CF and P. aeruginosa. The mean age was 30 years, and the mean baseline FEV1 % predicted was 55%; 43% were females and 96% were Caucasian. These patients were randomized in a 1:1 ratio to receive either CAYSTON (75 mg) or volume-matched placebo administered by inhalation 3 times a day for 28 days. Patients were required to have been off antibiotics for at least 28 days before treatment with study drug. The primary efficacy endpoint was improvement in respiratory symptoms on the last day of treatment with CAYSTON or placebo. Respiratory symptoms were also assessed two weeks after the completion of treatment with CAYSTON or placebo. Changes in respiratory symptoms were assessed using a questionnaire that asks patients to report on symptoms like cough, wheezing, and sputum production.

Improvement in respiratory symptoms was noted for CAYSTON-treated patients relative to placebo-treated patients on the last day of drug treatment. Statistically significant improvements were seen in both adult and pediatric patients but were substantially smaller in adult patients. Two weeks after completion of treatment, a difference in respiratory symptoms between treatment groups was still present, though the difference was smaller.

Pulmonary function, as measured by FEV1 (L), increased from baseline in patients treated with CAYSTON (see Figure 1). The treatment difference at Day 28 between CAYSTON-treated and placebo-treated patients for percent change in FEV1 (L) was statistically significant at 10% (95% CI: 6%, 14%). Improvements in FEV1 were comparable between adult and pediatric patients. Two weeks after completion of drug treatment, the difference in FEV1 between CAYSTON and placebo groups had decreased to 6% (95% CI: 2%, 9%).

Figure 1 Adjusted Mean Percent Change in FEV1 from Baseline to Study End (Days 0–42)
BACKGROUND: Schistosomiasis is a zoonotic parasitic disorder induced by the infestation of schistosomes, a genus of trematodes. MicroRNAs (miRNAs) in egg-derived exosomes are crucial for modulating the host's immune responses and orchestrating the pathophysiological mechanisms. Although the exosomes secreted by S. japonicum contain abundant miRNAs, the specific roles of these miRNAs in the pathogenesis of schistosomiasis-induced hepatic fibrosis are yet to be comprehensively elucidated. The egg exosomes of S. japonicum secrete miRNA-30, a novel miRNA.
METHODS: In vitro, the effect of miRNA-30 was evaluated by transfecting HSCs with miRNA mimics. The target gene biosignature for miRNA-30 was predicted using the miRDB software. The effect of miRNA-30 in hepatic fibrosis was evaluated by either elevating its expression in healthy mice or by inhibiting its activity in infected mice by administration of recombinant adeno-associated virus serotype eight vectors expressing miRNA-30 or miRNA sponges.
RESULTS: This novel miRNA can activate hepatic stellate cells (HSCs), the prinary effector cells of hepatic fibrosis, in vitro, i.e., it significantly increases the fibrogenic factors Col1(α1), Col3(α1), and α-SMA at both mRNA and protein levels. In addition, miRNA-30 may activate HSCs by targeting the host RORA gene. In addition, in vivo experiments were conducted by administering a recombinant adeno-associated viral vector to modulate the expression levels of miRNA-30. The overexpression of miRNA-30 in healthy mice significantly elevated the expression of Col1(α1), Col3(α1), and α-SMA at both the transcriptomic and proteomic scales. This overexpression was coupled with a pronounced augmentation in the hepatic hydroxyproline content. Conversely, the in vivo silencing of miRNA-30 in infected mice induced a considerable reduction in the size of hepatic granulomas and areas of collagen deposition. Hence, in vivo, modulation of miRNA-30 expression may play a pivotal role in ameliorating the severity of hepatic fibrosis in mice afflicted with S. japonica.
CONCLUSIONS: The study results suggest that miRNA-30 may augment schistosomiasis-induced hepatic fibrosis through a probable interaction with the host RORA. Our study may improve the current theoretical framework regarding cross-species regulation by miRNAs of hepatic fibrosis in schistosomiasis.
A human urocortin-related peptide with significant sequence homology to the CRF neuropeptide family was identified. A mouse cDNA was isolated from whole brain poly (A+) RNA that encodes a predicted 38 amino acid peptide protein designated herein as urocortin II. Both human URP and mouse family members, CRF and urocortin (Ucn). These peptides are involved in the regulation of the hypothalamic-pituitary-adrenal axis under basal and stress conditions, suggesting a similar role for URP and Ucn II. Synthesized Ucn-II and URP peptide binds with higher affinity to CRF-R2 than to CRF-R1 Ucn II and human URP appear to be involved in the regulation of body temperature and appetite and may play a role in other stress related phenomenon. These findings identify Ucn II and human URP as a new members of the CRF family of neuropeptides, which are expressed centrally and bind to CRF-R2.
Desalanino insulin (i.e. insulin in which the C-terminal alanine groups have been removed) is prepared by treating an aqueous solution of insulin having an alkaline pH e.g. pH 7.8 with an aqueous solution of carboxypetidase having an alkaline pH e.g. pH 8.0, incubating 5 hours at 37 DEG C, and adjusting to pH 5.4 with hydrochloric acid to precipitate the desalamino insulin.  The insulin may be derived from the pancreas of pigs, cattle, whales and fish.  For injection, the insulin is dissolved in sterile water at pH 2 to 4, preferably buffered, and also containing sodium chloride and/or glycerin and a preservative such as phenol or m-cresol.  The desalanino insulin may be used per se, as zinc desalanino insulin, protamine desalanino insulin, histone desalamino insulin, globin desalanino insulin or protamine &c. zinc desalanino insulin.
A series of two treatments spaced 4 weeks apart that include platelet-rich plasma (PRP). platelet lysate (PL), and platelet poor plasma (PPP).
Patients undergo RT on days 1-5 and then undergo biopsy 3-10 days later. Beginning 0-7 days after biopsy, patients receive MK-3475 as in Arm A1.
Suitable for patients with high risk neuroblastoma who obtain CR after chemotherapy combined with surgery, radiotherapy and/or hematopoietic stem cell transplantation. The treatment cycle is repeated every 4 weeks for a total of 5 courses, and discontinuation of nasetuzumab and GM-CSF should be considered if disease progression or unacceptable toxicity occurs.
PHASE II STUDY C, D \& E: Patients with PD-L1 expression \>= 50% receive CIMAvax IM and pembrolizumab IV over 30 minutes. Treatment with CIMAvax repeats every 2 weeks for 4 doses during the loading phase and every 4 weeks during the maintenance phase in the absence of disease progression or unacceptable toxicity. Courses for pembrolizumab repeat every 4 weeks for 2 years in the absence of disease progression or unacceptable toxicity.